Seroresponse to SARS-CoV-2 Vaccines Among Maintenance Dialysis Patients
Am J Kidney Dis
.
2022 Feb;79(2):307-310.
doi: 10.1053/j.ajkd.2021.10.002.
Epub 2021 Nov 7.
Authors
Caroline M Hsu
1
,
Daniel E Weiner
2
,
Gideon N Aweh
3
,
Harold J Manley
3
,
Vladimir Ladik
3
,
Jill Frament
3
,
Dana Miskulin
2
,
Christos Argyropoulos
4
,
Kenneth Abreo
5
,
Andrew Chin
6
,
Reginald Gladish
7
,
Loay Salman
8
,
Doug Johnson
3
,
Eduardo K Lacson
9
Affiliations
1
Tufts Medical Center, Boston, Massachusetts. Electronic address: chsu1@tuftsmedicalcenter.org.
2
Tufts Medical Center, Boston, Massachusetts.
3
Dialysis Clinic Inc (DCI), Nashville, Tennessee.
4
University of New Mexico, Albuquerque, New Mexico.
5
Louisiana State University Health Sciences Center, Shreveport, Louisiana.
6
University of California, Davis, Sacramento, California.
7
Nephrology of North Alabama, Decatur, Alabama.
8
Albany Medical College, Albany, New York.
9
Tufts Medical Center, Boston, Massachusetts; Dialysis Clinic Inc (DCI), Nashville, Tennessee.
PMID:
34758369
PMCID:
PMC8572553
DOI:
10.1053/j.ajkd.2021.10.002
No abstract available
Publication types
Letter
Research Support, Non-U.S. Gov't
MeSH terms
COVID-19 Vaccines*
COVID-19*
Humans
Immunogenicity, Vaccine
Renal Dialysis
SARS-CoV-2
Substances
COVID-19 Vaccines